bioAffinity Technologies closes $1.8M registered direct offering of 720K shares at $2.50/share

bioAffinity Technologies, Inc.

Issued 720,000 shares of common stock at $2.50/share; gross proceeds of ~$1.8M before fees.
Net proceeds to fund working capital, support growing sales of CyPath® Lung, and general corporate purposes.
Officers and directors subject to 60-day lock-up; company restricted from further equity issuance until Nov 14, 2025.
WallachBeth Capital acted as sole placement agent; received 8.0% cash fee plus up to $75K expenses.
Offering closed on October 9, 2025; shares sold under effective shelf registration statement on Form S-3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.